Literature DB >> 15138179

Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.

James A DeVoti1, Bettie M Steinberg, David W Rosenthal, Lynda Hatam, Andrea Vambutas, Allan L Abramson, Mark J Shikowitz, Vincent R Bonagura.   

Abstract

Recurrent respiratory papillomatosis (RRP) is a chronic, debilitating disease of the upper airway caused by human papillomavirus type 6 (HPV-6) or HPV-11. We describe responses of peripheral blood mononuclear cells (PBMC) and T cells from RRP patients and controls to the HPV-11 early proteins E6 and E7. PBMC were exposed in vitro to purified E6 or E7 proteins or transduced with fusion proteins containing the first 11 amino acids of the human immunodeficiency virus type 1 protein tat fused to E6 or E7 (tat-E6/tat-E7). T(H)1-like (interleukin-2 [IL-2], gamma interferon [IFN-gamma], IL-12, and IL-18), and T(H)2-like (IL-4 and IL-10) cytokine mRNAs were identified by reverse transcription-PCR, and IFN-gamma and IL-10 cytokine-producing cells were identified by enzyme-linked immunospot assay. These studies show that HPV-11 E6 skews IL-10-IFN-gamma expression by patients with RRP toward greater expression of IL-10 than of IFN-gamma. In addition, there is a general cytokine hyporesponsiveness to E6 that is more prominent for T(H)1-like cytokine expression by patients with severe disease. Patients showed persistent IL-10 cytokine expression by the nonadherent fraction of PBMC when challenged with E6 and tat-E6, and, in contrast to controls, both T cells and non-T cells from patients expressed IL-10. However, E7/tat-E7 cytokine responses in patients with RRP were similar to those of the controls. In contrast, E6 inhibited IL-2 and IL-18 mRNA expression that would further contribute to a cytokine microenvironment unfavorable to HPV-specific, T-cell responses that should control persistent HPV infection. In summary, E6 is the dominant inducer of cytokine expression in RRP, and it induces a skewed expression of IL-10 compared to the expression of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138179      PMCID: PMC404580          DOI: 10.1128/CDLI.11.3.538-547.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  57 in total

Review 1.  Regulatory T cells: key controllers of immunologic self-tolerance.

Authors:  S Sakaguchi
Journal:  Cell       Date:  2000-05-26       Impact factor: 41.582

Review 2.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection.

Authors:  S Wirth; M van den Broek; C P Frossard; A W Hügin; I Leblond; H Pircher; C Hauser
Journal:  Cell Immunol       Date:  2000-05-25       Impact factor: 4.868

Review 4.  Dendritic cell regulation of TH1-TH2 development.

Authors:  M Moser; K M Murphy
Journal:  Nat Immunol       Date:  2000-09       Impact factor: 25.606

5.  Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; S Pecorelli; J J Roman; G P Parham; M J Cannon
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 6.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 7.  Mouse and human dendritic cell subtypes.

Authors:  Ken Shortman; Yong-Jun Liu
Journal:  Nat Rev Immunol       Date:  2002-03       Impact factor: 53.106

8.  Respective involvement of TGF-beta and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors.

Authors:  C Caux; C Massacrier; B Dubois; J Valladeau; C Dezutter-Dambuyant; I Durand; D Schmitt; S Saeland
Journal:  J Leukoc Biol       Date:  1999-11       Impact factor: 4.962

9.  Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle.

Authors:  L R Armstrong; E J Preston; M Reichert; D L Phillips; R Nisenbaum; N W Todd; I N Jacobs; A F Inglis; S C Manning; W C Reeves
Journal:  Clin Infect Dis       Date:  2000-07-11       Impact factor: 9.079

10.  CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

Authors:  J M den Haan; S M Lehar; M J Bevan
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

View more
  23 in total

1.  Interferon-γ Treatment of Human Laryngotracheal Stenosis-Derived Fibroblasts.

Authors:  Kevin Motz; Idris Samad; Linda X Yin; Michael K Murphy; Madhavi Duvvuri; Dacheng Ding; Alexander T Hillel
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-11-01       Impact factor: 6.223

2.  Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.

Authors:  James DeVoti; Lynda Hatam; Alexandra Lucs; Ali Afzal; Allan Abramson; Bettie Steinberg; Vincent Bonagura
Journal:  Mol Med       Date:  2014-08-28       Impact factor: 6.354

3.  Management of adult recurrent respiratory papillomatosis with oral acyclovir following micro laryngeal surgery: a case series.

Authors:  Jagdish Chaturvedi; V Sreenivas; V Hemanth; R Nandakumar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-06

4.  T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis.

Authors:  David W Rosenthal; James A DeVoti; Bettie M Steinberg; Allan L Abramson; Vincent R Bonagura
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

5.  Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis.

Authors:  Eddie A James; James A DeVoti; David W Rosenthal; Lynda J Hatam; Bettie M Steinberg; Allan L Abramson; William W Kwok; Vincent R Bonagura
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

Review 6.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Authors:  Vincent R Bonagura; Lynda J Hatam; David W Rosenthal; James A de Voti; Fung Lam; Bettie M Steinberg; Allan L Abramson
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

7.  Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.

Authors:  Vincent R Bonagura; Zeying Du; Elham Ashouri; Lihui Luo; Lynda J Hatam; James A DeVoti; David W Rosenthal; Bettie M Steinberg; Allan L Abramson; David W Gjertson; Elaine F Reed; Raja Rajalingam
Journal:  Hum Immunol       Date:  2009-10-25       Impact factor: 2.850

8.  Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis.

Authors:  James A DeVoti; David W Rosenthal; Rong Wu; Allan L Abramson; Bettie M Steinberg; Vincent R Bonagura
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

Review 9.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

Review 10.  Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.

Authors:  R Ivancic; H Iqbal; B deSilva; Q Pan; L Matrka
Journal:  Clin Exp Immunol       Date:  2019-10-31       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.